Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered
High rates of virological suppression were maintained during OB. Oral 300 mg QW LEN was well tolerated and provided adequate plasma concentrations to bridge SC LEN dosing. This analysis supports using 300 mg QW LEN for OB when SC LEN treatment is interrupted.
Authors
- Onyema Ogbuagu (ORCID: https://orcid.org/0000-0001-7342-2608)
- Peter Sklar (ORCID: https://orcid.org/0009-0000-7071-6942)
- Hadas Dvory‐Sobol (ORCID: https://orcid.org/0000-0003-0716-2750)
- Anchalee Avihingsanon (ORCID: https://orcid.org/0000-0003-3222-9611)
- Sorana Segal-Maurer
- Jean‐Michel Molina (ORCID: https://orcid.org/0000-0001-8684-2214)
- Vamshi Jogiraju (ORCID: https://orcid.org/0000-0001-5181-3392)
- Hui Wang (ORCID: https://orcid.org/0000-0002-0249-0432)
- Martin S. Rhee (ORCID: https://orcid.org/0000-0001-5263-9613)
- Renu Singh
Institutions
- Chulalongkorn University (TH)
- New York Hospital Queens (US)
- Yale University (US)
- HIV Netherlands Australia Thailand Research Collaboration (TH)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- AIDS
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1097/qad.0000000000004142
- Citations
- 5
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.18